Research programme: immunotherapy and gene inhibition - Juvaris/SomaGenicsAlternative Names: Immunotherapy and gene inhibition research programme - Juvaris/SomaGenics
Latest Information Update: 26 Dec 2014
At a glance
- Originator Juvaris BioTherapeutics; SomaGenics
- Class DNA; Lipids; RNA
- Mechanism of Action Genetic transcription inhibitors; Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Anthrax
Most Recent Events
- 02 Jun 2004 Preclinical trials in Anthrax in USA (unspecified route)